EP Patent

EP3184524A1 — 4-hydroxy-2-phenyl-1,3-thiazol-5-yl methanone derivatives as trpm8 antagonists

Assigned to Dompe Farmaceutici SpA · Expires 2017-06-28 · 9y expired

What this patent protects

The invention relates to compounds acting as antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I): Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, ischae…

USPTO Abstract

The invention relates to compounds acting as antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I): Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold-induced and/or exacerbated- respiratory disorders, urological disorders, corneal disordes associated to disturbances in the production of the tears and/or altered blinking such as epiphora and dry eye disease.

Drugs covered by this patent

Patent Metadata

Patent number
EP3184524A1
Jurisdiction
EP
Classification
—
Expires
2017-06-28
Drug substance claim
No
Drug product claim
No
Assignee
Dompe Farmaceutici SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.